AJP - Heart AJP citation statistics
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Heart Circ Physiol 288: H2042-H2046, 2005; doi:10.1152/ajpheart.00669.2004
0363-6135/05 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (5)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Matsunaga, T.
Right arrow Articles by March, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Matsunaga, T.
Right arrow Articles by March, K.

TRANSLATIONAL PHYSIOLOGY

Angiostatin is negatively associated with coronary collateral growth in patients with coronary artery disease

Toshiro Matsunaga,1 William M. Chilian,3 and Keith March2

1Second Department of Internal Medicine, Hirosaki University School of Medicine, Hirosaki, Japan; 2Department of Medicine and Center for Vascular Biology, Indiana University Medical School, Indianapolis, Indiana; and 3Department of Physiology, Louisiana State University Health Science Center, New Orleans, Louisiana

Submitted 6 July 2004 ; accepted in final form 14 December 2004

Angiostatin, an inhibitor of tumor angiogenesis, is produced by the actions of matrix metalloproteinases (MMP) on plasminogen. Recently, we reported that angiostatin levels are increased in a model of inadequate coronary collateral growth and angiogenesis in response to ischemia, despite high levels of vascular endothelial growth factor (VEGF). We hypothesized that angiostatin levels are negatively associated with collateral formation in patients. Coronary angiograms from 37 patients undergoing coronary bypass surgery were evaluated for the absence of angiographically visible collaterals (Rentrop scores of 0) or the presence of Rentrop classification grade 3 (well developed) collaterals. Pericardial fluid was obtained from each patient during the bypass procedure, and the sample was analyzed for angiostatin, plasminogen, and VEGF (Western analysis) and for combined activities of MMP-2 and MMP-9 (zymographic analysis). In patients with no collaterals, angiostatin level was greater compared with that in patients with well-developed collaterals (3.1 ± 0.2 vs. 2.3 ± 0.1 optical density units, P < 0.05). Neither MMP activities nor VEGF levels were different between the two groups of patients. The higher levels of angiostatin in patients with no visible collaterals were reflective of a higher concentration of plasmin/plasminogen (6.2 ± 0.7 vs. 4.2 ± 0.5 optical density units, P < 0.05) compared with those in patients with well-developed collateral vessels. Our results support the concept that the growth inhibitor angiostatin may have a negative impact on coronary collateral growth in patients. Perhaps therapies attempting to provoke coronary collateral growth should incorporate approaches to limit or neutralize the effects of growth inhibitors.

vascular endothelial growth factor; matrix metalloproteinase; plasminogen



Address for reprint requests and other correspondence: W. M. Chilian, Dept. of Physiology, Louisiana State Univ. Health Sciences Center, 1901 Perdido St., New Orleans, LA 70112 (E-mail: chilian{at}lsuhsc.edu)




This article has been cited by other articles:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
N. R. Sodha, R. T. Clements, M. Boodhwani, S.-H. Xu, R. J. Laham, C. Bianchi, and F. W. Sellke
Endostatin and angiostatin are increased in diabetic patients with coronary artery disease and associated with impaired coronary collateral formation
Am J Physiol Heart Circ Physiol, February 1, 2009; 296(2): H428 - H434.
[Abstract] [Full Text] [PDF]


Home page
Arch SurgHome page
N. R. Sodha, M. Boodhwani, R. T. Clements, S.-H. Xu, K. R. Khabbaz, and F. W. Sellke
Increased Antiangiogenic Protein Expression in the Skeletal Muscle of Diabetic Swine and Patients
Arch Surg, May 1, 2008; 143(5): 463 - 470.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
M. Boodhwani, N. R. Sodha, S. Mieno, B. Ramlawi, S.-H. Xu, J. Feng, R. T. Clements, M. Ruel, and F. W. Sellke
Insulin treatment enhances the myocardial angiogenic response in diabetes.
J. Thorac. Cardiovasc. Surg., December 1, 2007; 134(6): 1453 - 1460.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
D. Weihrauch, H. Xu, Y. Shi, J. Wang, J. Brien, D. W. Jones, S. Kaul, R. A. Komorowski, M. E. Csuka, K. T. Oldham, et al.
Effects of D-4F on vasodilation, oxidative stress, angiostatin, myocardial inflammation, and angiogenic potential in tight-skin mice
Am J Physiol Heart Circ Physiol, September 1, 2007; 293(3): H1432 - H1441.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2005 by the American Physiological Society.